Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro

• Autors principals: Johanna Weiss (Autor), Dirk Theile (Autor), Zdenek Dvorak (Autor), Walter Emil Haefeli (Autor)
• Format: Llibre
• Publicat: MDPI AG, 2014-12-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Dovitinib (TKI-258) is under development for the treatment of diverse cancer entities. No published information on its pharmacokinetic drug interaction potential is available. Thus, we assessed its interaction with important drug metabolising enzymes and drug transporters and its efficacy in multidr...